For the assessment of the efficacy of anticoagulant therapy in patients with symptomatic venous thrombosis, the incidence of symptomatic venous thromboembolic complications is the outcome measure of choice. However, the low incidence of such complications necessitates the inclusion of a prohibitively large number of patients in randomized trials evaluating anticoagulant regimens. Therefore, alternative efficacy outcome measures are desirable. This paper discusses the validity of the following alternative tests: venography and compression ultrasound for deep vein thrombosis; and pulmonary angiography and perfusion lung scanning for pulmonary embolism. It is concluded that a combination of one of the deep vein thrombosis tests and perfusion lung scanning is the optimal approach. A thrombotic burden assessment, using repeat venography and perfusion lung scanning, has been performed at the end of treatment (day 10) with low-molecular-weight heparin and unfractionated heparin in 170 patients with symptomatic proximal deep vein thrombosis. An improved thrombotic burden was associated with a low number of subsequent symptomatic venous thromboembolic complications (4%), whereas this figure gradually increased for patients with an unchanged (10%) and deteriorated (29%) outcome (p < 0.005). It is concluded that the thrombotic burden assessment has potential to replace symptomatic outcomes, especially in dose-finding studies.

Keywords:
Venous thromboembolism, Venography, Ultrasound, Angiography, Endpoints, Low-molecular-weight heparin, Unfractionated heparin
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.